Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Calcobutrol SCHEMBL22763151 | 1.00 | SLC6A9 (0.43) | SLC6A9HSD17B10CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL12671512 | 1.00 | SLC6A9 (0.43) | SLC6A9HSD17B10CACNA2D1CACNA1BCACNB1 | |
| Calcobutrol SCHEMBL29764073 | 1.00 | SLC6A9 (0.43) | SLC6A9HSD17B10CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL23802704 | 1.00 | SLC6A9 (0.43) | SLC6A9HSD17B10CACNA2D1CACNA1BCACNB1 | |
| Calcobutrol SCHEMBL16479551 | 1.00 | SLC6A9 (0.43) | SLC6A9HSD17B10CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL23802703 | 1.00 | SLC6A9 (0.43) | SLC6A9HSD17B10CACNA2D1CACNA1BCACNB1 | |
| Calcobutrol SCHEMBL10024738 | 1.00 | SLC6A9 (0.43) | SLC6A9HSD17B10CACNA2D1CACNA1BCACNB1 | |
| Calcobutrol SCHEMBL20540234 | 1.00 | SLC6A9 (0.43) | SLC6A9HSD17B10CACNA2D1CACNA1BCACNB1 | |
| Calcobutrol SCHEMBL21618318 | 0.98 | SLC6A9 (0.42) | SLC6A9HSD17B10CACNA2D1CACNA1BCACNB1 | |
| Calcobutrol SCHEMBL14834269 | 0.98 | SLC6A9 (0.42) | SLC6A9HSD17B10CACNA2D1CACNA1BCACNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 370 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12303573-B2 | Formulation of contrast media and process of preparation thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-05-20 | — | — | US | claimed |
| US-20250152753-A1 | FORMULATION OF CONTRAST MEDIA AND PROCESS OF PREPARATION THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-05-15 | — | — | US | claimed |
| US-20240252690-A1 | FORMULATION OF CONTRAST MEDIA AND PROCESS OF PREPARATION THEREOF | BAYER AG (DE) | 2024-08-01 | — | — | US | claimed |
| WO-2024100233-A1 | GENERATION OF ARTIFICIAL CONTRAST-ENHANCED RADIOLOGICAL IMAGES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-16 | — | — | WO | claimed |
| EP-4369353-A1 | GENERATION OF ARTIFICIAL CONTRAST AGENT-ENHANCED RADIOLOGICAL RECORDINGS | Bayer Aktiengesellschaft (DE) | 2024-05-15 | — | — | EP | claimed |
| US-11944690-B2 | Formulation of contrast media and process of preparation thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-02 | — | — | US | claimed |
| WO-2024052156-A1 | GENERATION OF ARTIFICIAL CONTRAST-ENHANCED RADIOLOGICAL IMAGES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-14 | — | — | WO | claimed |
| WO-2024046831-A1 | GENERATION OF SYNTHETIC RADIOLOGICAL IMAGES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-07 | — | — | WO | claimed |
| WO-2024046833-A1 | GENERATION OF SYNTHETIC RADIOLOGICAL IMAGES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-07 | — | — | WO | claimed |
| WO-2024046832-A1 | GENERATION OF SYNTHETIC RADIOLOGICAL IMAGES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-07 | — | — | WO | claimed |
| WO-2011054480-A1 | GADOBUTROL PRODUCTION BY MEANS OF A CERAMIC MEMBRANE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-12 | — | — | WO | claimed |
| EP-0986548-B1 | PRODUCTION OF MONO AND 1,7-BIS-N-HYDROXYALKYL-CYCLENE AND LITHIUM SALT COMPLEXES | SCHERING AG (DE) | 2003-07-30 | — | — | EP | claimed |
| US-20020176823-A1 | 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2002-11-28 | — | — | US | claimed |
| US-6042810-A | Process for the preparation of macrocyclic chelants and the chelates thereof with paramagnetic metal ions | DIBRA S.P.A. (IT) | 2000-03-28 | — | — | US | claimed |
| US-5980864-A | 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them | SCHERING AKTIENGELLSELLSCHAFT (DE) | 1999-11-09 | — | — | US | claimed |
| EP-0596586-B1 | Process for the production of metal complexes of N-beta-hydroxalkyl-tri-N-carboxyalkyl-1,4,7,10-tetraazacyclododecane and derivatives thereof | SCHERING AG (DE) | 1997-01-22 | — | — | EP | claimed |
| EP-0448191-B1 | 1,4,7,10-Tetraazacyclododecane-butyltriols, process for their preparation, and pharmaceutical agents containing these compounds | SCHERING AG (DE) | 1995-06-28 | — | — | EP | claimed |
| US-5410043-A | Chemical intermediate for metal complexes | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-04-25 | — | — | US | claimed |
| EP-0596586-A1 | Process for the production of metal complexes of N-beta-hydroxalkyl-tri-N-carboxyalkyl-1,4,7,10-tetraazacyclododecane and derivatives thereof | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-05-11 | — | — | EP | claimed |
| EP-0448191-A1 | 1,4,7,10-Tetraazacyclododecane-butyltriols, process for their preparation, and pharmaceutical agents containing these compounds | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-09-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12303573-B2 | Formulation of contrast media and process of preparation thereof | RXFP3, SLC6A3, PDE3A | SLC6A9 401/4885HSD17B10 4735/4885CACNA2D1 2934/4885 |
| US-20250152753-A1 | FORMULATION OF CONTRAST MEDIA AND PROCESS OF PREPARATION THEREOF | RXFP3, SLC6A3, PDE3A | SLC6A9 401/4885HSD17B10 4735/4885CACNA2D1 2934/4885 |
| US-20240252690-A1 | FORMULATION OF CONTRAST MEDIA AND PROCESS OF PREPARATION THEREOF | RXFP3, SLC6A3, PDE3A | SLC6A9 401/4885HSD17B10 4735/4885CACNA2D1 2934/4885 |
| US-11944690-B2 | Formulation of contrast media and process of preparation thereof | RXFP3, SLC39A3, F12 | SLC6A9 128/4885HSD17B10 4846/4885CACNA2D1 4487/4885 |
| US-20020176823-A1 | 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them | CYP11B1, CYP11B2, BBOX1 | SLC6A9 1944/4885HSD17B10 49/4885CACNA2D1 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.